Janus Henderson Concentrated Growth Managed Account Q1 2025 Commentary
Source: SeekingAlpha
2025-05-20 04:02:00 ET
Summary
- Janus Henderson Concentrated Growth Managed Account portfolio returned -8.89% (gross) and the Russell 1000® Growth Index returned -10.00%.
- Stock selection in the consumer discretionary and financials sectors contributed to relative performance, while selection in information technology and healthcare detracted.
- Despite significant near-term volatility, we continue to focus on competitively advantaged companies positioning themselves for market share gains when conditions stabilize.
Performance - USD (%)
| Cumulative | Annualized | ||||||
| Returns | 1Q25 | YTD | 1 Yr | 3 Yr | 5 Yr | 10 Yr | Since Inception (10/01/94) |
| Composite (pure gross*) | -8.89 | -8.89 | 3.64 | 7.55 | 16.78 | 13.94 | 14.47 |
| Composite (Net) | -9.58 | -9.58 | 0.62 | 4.42 | 13.4 | 10.64 | 11.14 |
| Russell 1000 ® Growth Index | -10 | -10 | 7.72 | 10.08 | 20.08 | 15.11 | 11 |
Read the full article on Seeking Alpha
For further details see:
Janus Henderson Concentrated Growth Managed Account Q1 2025 Commentary
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-5.35% G/L:
$53.39 Last:
575,994 Volume:
$57.06 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
